Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Gemcitabine and Floxuridine for NPC Liver Metastases
NCT03876574Phase 1Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2011
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of gemcitabine and floxuridine in nasopharyngeal carcinoma (NPC), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Disease Control Rate at 2 years. Started Jan 2011; status: completed.
02
Drugs
gemcitabinefloxuridine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03876574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876574.